Dr. Dubovsky is executive vice president, chief medical officer with responsibility for medical and clinical affairs and related activities at Novavax. A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joined Novavax from AstraZeneca, where he was head of clinical engagement and policy and deputy chief medical officer for clinical affairs. Before that, he oversaw the clinical development of early and late-stage infectious disease and vaccine assets at MedImmune, which was subsequently acquired by AstraZeneca. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He is the coauthor of more than 50 peer-reviewed scientific publications and currently sits on the board of directors of the Sabin Institute. Dr. Dubovsky earned his master of public health degree from Johns Hopkins University and his doctor of medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.